TY - JOUR AU - Pao, W. AU - Miller, V. AU - Zakowski, M. AU - Doherty, J. AU - Politi, K. AU - Sarkaria, I. AU - Singh, B. AU - Heelan, R. AU - Rusch, V. AU - Fulton, L. PY - 2004 DA - 2004// TI - EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib JO - Proc Natl Acad Sci U S A VL - 101 UR - https://doi.org/10.1073/pnas.0405220101 DO - 10.1073/pnas.0405220101 ID - Pao2004 ER - TY - JOUR AU - Tan, D. S. AU - Yom, S. S. AU - Tsao, M. S. AU - Pass, H. I. AU - Kelly, K. AU - Peled, N. AU - Yung, R. C. AU - Wistuba, I. I. AU - Yatabe, Y. AU - Unger, M. PY - 2016 DA - 2016// TI - The International Association for the Study of Lung Cancer consensus statement on optimizing management of EGFR mutation-positive non-small cell lung Cancer: status in 2016 JO - J Thorac Oncol VL - 11 UR - https://doi.org/10.1016/j.jtho.2016.05.008 DO - 10.1016/j.jtho.2016.05.008 ID - Tan2016 ER - TY - JOUR AU - Schuler, M. AU - Wu, Y. L. AU - Hirsh, V. AU - O'Byrne, K. AU - Yamamoto, N. AU - Mok, T. AU - Popat, S. AU - Sequist, L. V. AU - Massey, D. AU - Zazulina, V. PY - 2016 DA - 2016// TI - First-line Afatinib versus chemotherapy in patients with non-small cell lung Cancer and common epidermal growth factor receptor gene mutations and brain metastases JO - J Thorac Oncol VL - 11 UR - https://doi.org/10.1016/j.jtho.2015.11.014 DO - 10.1016/j.jtho.2015.11.014 ID - Schuler2016 ER - TY - JOUR AU - Iuchi, T. AU - Shingyoji, M. AU - Itakura, M. AU - Yokoi, S. AU - Moriya, Y. AU - Tamura, H. AU - Yoshida, Y. AU - Ashinuma, H. AU - Kawasaki, K. AU - Hasegawa, Y. PY - 2015 DA - 2015// TI - Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations JO - Int J Clin Oncol VL - 20 UR - https://doi.org/10.1007/s10147-014-0760-9 DO - 10.1007/s10147-014-0760-9 ID - Iuchi2015 ER - TY - JOUR AU - Jain, A. AU - Lim, C. AU - Gan, E. M. AU - Ng, D. Z. AU - Ng, Q. S. AU - Ang, M. K. AU - Takano, A. AU - Chan, K. S. AU - Tan, W. M. AU - Kanesvaran, R. PY - 2015 DA - 2015// TI - Impact of smoking and brain metastasis on outcomes of advanced EGFR mutation lung adenocarcinoma patients treated with first line epidermal growth factor receptor tyrosine kinase inhibitors JO - PLoS One VL - 10 UR - https://doi.org/10.1371/journal.pone.0123587 DO - 10.1371/journal.pone.0123587 ID - Jain2015 ER - TY - JOUR AU - Hoffknecht, P. AU - Tufman, A. AU - Wehler, T. AU - Pelzer, T. AU - Wiewrodt, R. AU - Schütz, M. AU - Serke, M. AU - Stöhlmacher-Williams, J. AU - Märten, A. AU - Huber, R. M. PY - 2015 DA - 2015// TI - Efficacy of the irreversible ErbB family blocker afatinib in epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)–pretreated non–small-cell lung cancer patients with brain metastases or leptomeningeal disease JO - J Thorac Oncol VL - 10 UR - https://doi.org/10.1097/JTO.0000000000000380 DO - 10.1097/JTO.0000000000000380 ID - Hoffknecht2015 ER - TY - JOUR AU - Yang, J. -. H. AU - Sequist, L. AU - Zhou, C. AU - Schuler, M. AU - Geater, S. AU - Mok, T. AU - Hu, C. -. P. AU - Yamamoto, N. AU - Feng, J. AU - O'byrne, K. PY - 2016 DA - 2016// TI - Effect of dose adjustment on the safety and efficacy of afatinib for EGFR mutation-positive lung adenocarcinoma: post hoc analyses of the randomized LUX-lung 3 and 6 trials JO - Ann Oncol VL - 27 UR - https://doi.org/10.1093/annonc/mdw322 DO - 10.1093/annonc/mdw322 ID - Yang2016 ER - TY - JOUR AU - Lynch, T. J. AU - Bell, D. W. AU - Sordella, R. AU - Gurubhagavatula, S. AU - Okimoto, R. A. AU - Brannigan, B. W. AU - Harris, P. L. AU - Haserlat, S. M. AU - Supko, J. G. AU - Haluska, F. G. PY - 2004 DA - 2004// TI - Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung Cancer to Gefitinib JO - N Engl J Med VL - 350 UR - https://doi.org/10.1056/NEJMoa040938 DO - 10.1056/NEJMoa040938 ID - Lynch2004 ER - TY - JOUR AU - Lopez-Rios, F. AU - Angulo, B. AU - Gomez, B. AU - Mair, D. AU - Martinez, R. AU - Conde, E. AU - Shieh, F. AU - Tsai, J. AU - Vaks, J. AU - Current, R. PY - 2013 DA - 2013// TI - Comparison of molecular testing methods for the detection of EGFR mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer JO - J Clin Pathol VL - 66 UR - https://doi.org/10.1136/jclinpath-2012-201240 DO - 10.1136/jclinpath-2012-201240 ID - Lopez-Rios2013 ER - TY - JOUR AU - Pirker, R. AU - Herth, F. J. AU - Kerr, K. M. AU - Filipits, M. AU - Taron, M. AU - Gandara, D. AU - Hirsch, F. R. AU - Grunenwald, D. AU - Popper, H. AU - Smit, E. PY - 2010 DA - 2010// TI - Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop JO - J Thorac Oncol VL - 5 UR - https://doi.org/10.1097/JTO.0b013e3181f1c8de DO - 10.1097/JTO.0b013e3181f1c8de ID - Pirker2010 ER - TY - JOUR AU - Lindeman, N. I. AU - Cagle, P. T. AU - Beasley, M. B. AU - Chitale, D. A. AU - Dacic, S. AU - Giaccone, G. AU - Jenkins, R. B. AU - Kwiatkowski, D. J. AU - Saldivar, J. S. AU - Squire, J. PY - 2013 DA - 2013// TI - Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology JO - J Thorac Oncol VL - 8 UR - https://doi.org/10.1097/JTO.0b013e318290868f DO - 10.1097/JTO.0b013e318290868f ID - Lindeman2013 ER - TY - JOUR AU - Sequist, L. V. AU - Yang, J. C. AU - Yamamoto, N. AU - O'Byrne, K. AU - Hirsh, V. AU - Mok, T. AU - Geater, S. L. AU - Orlov, S. AU - Tsai, C. M. AU - Boyer, M. PY - 2013 DA - 2013// TI - Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations JO - J Clin Oncol VL - 31 UR - https://doi.org/10.1200/JCO.2012.44.2806 DO - 10.1200/JCO.2012.44.2806 ID - Sequist2013 ER - TY - JOUR AU - Wu, Y. -. L. AU - Zhou, C. AU - Hu, C. -. P. AU - Feng, J. AU - Lu, S. AU - Huang, Y. AU - Li, W. AU - Hou, M. AU - Shi, J. H. AU - Lee, K. Y. PY - 2014 DA - 2014// TI - Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-lung 6): an open-label, randomised phase 3 trial JO - Lancet Oncol VL - 15 UR - https://doi.org/10.1016/S1470-2045(13)70604-1 DO - 10.1016/S1470-2045(13)70604-1 ID - Wu2014 ER - TY - JOUR AU - Yang, C. -. J. AU - Tsai, M. -. J. AU - Hung, J. -. Y. AU - Lee, M. -. H. AU - Tsai, Y. -. M. AU - Tsai, Y. -. C. AU - Hsu, J. -. F. AU - Liu, T. -. C. AU - Huang, M. -. S. AU - Chong, I. -. W. PY - 2017 DA - 2017// TI - The clinical efficacy of Afatinib 30 mg daily as starting dose may not be inferior to Afatinib 40 mg daily in patients with stage IV lung adenocarcinoma harboring exon 19 or exon 21 mutations JO - BMC Pharmacol Toxicol VL - 18 UR - https://doi.org/10.1186/s40360-017-0190-1 DO - 10.1186/s40360-017-0190-1 ID - Yang2017 ER - TY - JOUR AU - Girard, N. PY - 2018 DA - 2018// TI - Optimizing outcomes in EGFR mutation-positive NSCLC: which tyrosine kinase inhibitor and when? JO - Future Oncol. (London, England) VL - 14 UR - https://doi.org/10.2217/fon-2017-0636 DO - 10.2217/fon-2017-0636 ID - Girard2018 ER - TY - JOUR AU - Yap, T. A. AU - Vidal, L. AU - Adam, J. AU - Stephens, P. AU - Spicer, J. AU - Shaw, H. AU - Ang, J. AU - Temple, G. AU - Bell, S. AU - Shahidi, M. PY - 2010 DA - 2010// TI - Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors JO - J Clin Oncol VL - 28 UR - https://doi.org/10.1200/JCO.2009.26.7278 DO - 10.1200/JCO.2009.26.7278 ID - Yap2010 ER - TY - JOUR AU - Hochmair, M. AU - Holzer, S. AU - Burghuber, O. C. PY - 2016 DA - 2016// TI - Complete remissions in afatinib-treated non-small-cell lung cancer patients with symptomatic brain metastases JO - Anti-Cancer Drugs VL - 27 UR - https://doi.org/10.1097/CAD.0000000000000410 DO - 10.1097/CAD.0000000000000410 ID - Hochmair2016 ER - TY - JOUR AU - Tamiya, A. AU - Tamiya, M. AU - Nishihara, T. AU - Shiroyama, T. AU - Nakao, K. AU - Tsuji, T. AU - Takeuchi, N. AU - Isa, S. -. I. AU - Omachi, N. AU - Okamoto, N. PY - 2017 DA - 2017// TI - Cerebrospinal fluid penetration rate and efficacy of Afatinib in patients with EGFR mutation-positive non-small cell lung Cancer with leptomeningeal Carcinomatosis: a multicenter prospective study JO - Anticancer Res VL - 37 ID - Tamiya2017 ER - TY - JOUR AU - Zhu, Y. AU - Du, Y. AU - Liu, H. AU - Ma, T. AU - Shen, Y. AU - Pan, Y. PY - 2016 DA - 2016// TI - Study of efficacy and safety of pulsatile administration of high-dose gefitinib or erlotinib for advanced non-small cell lung cancer patients with secondary drug resistance: a single center, single arm, phase II clinical trial JO - Thorac Cancer VL - 7 UR - https://doi.org/10.1111/1759-7714.12384 DO - 10.1111/1759-7714.12384 ID - Zhu2016 ER - TY - JOUR AU - Grommes, C. AU - Oxnard, G. R. AU - Kris, M. G. AU - Miller, V. A. AU - Pao, W. AU - Holodny, A. I. AU - Clarke, J. L. AU - Lassman, A. B. PY - 2011 DA - 2011// TI - “Pulsatile” high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer JO - Neuro-Oncology VL - 13 UR - https://doi.org/10.1093/neuonc/nor121 DO - 10.1093/neuonc/nor121 ID - Grommes2011 ER - TY - JOUR AU - Camidge, D. R. AU - Sequist, L. V. AU - Janne, P. A. AU - Weickhardt, A. J. AU - Dowling, E. S. AU - Alicea, J. AU - Fan, J. AU - Oxnard, G. R. PY - 2018 DA - 2018// TI - Phase Ib study of high-dose intermittent Afatinib in patients with advanced solid tumors JO - Clin Lung Cancer VL - 19 UR - https://doi.org/10.1016/j.cllc.2018.04.015 DO - 10.1016/j.cllc.2018.04.015 ID - Camidge2018 ER -